341 related articles for article (PubMed ID: 27086914)
1. The oleocanthal-based homovanillyl sinapate as a novel c-Met inhibitor.
Mohyeldin MM; Akl MR; Ebrahim HY; Dragoi AM; Dykes S; Cardelli JA; El Sayed KA
Oncotarget; 2016 May; 7(22):32247-73. PubMed ID: 27086914
[TBL] [Abstract][Full Text] [Related]
2. Olive phenolics as c-Met inhibitors: (-)-Oleocanthal attenuates cell proliferation, invasiveness, and tumor growth in breast cancer models.
Akl MR; Ayoub NM; Mohyeldin MM; Busnena BA; Foudah AI; Liu YY; Sayed KA
PLoS One; 2014; 9(5):e97622. PubMed ID: 24849787
[TBL] [Abstract][Full Text] [Related]
3. Novel c-Met inhibitory olive secoiridoid semisynthetic analogs for the control of invasive breast cancer.
Mohyeldin MM; Busnena BA; Akl MR; Dragoi AM; Cardelli JA; El Sayed KA
Eur J Med Chem; 2016 Aug; 118():299-315. PubMed ID: 27258622
[TBL] [Abstract][Full Text] [Related]
4. The indole alkaloid meleagrin, from the olive tree endophytic fungus Penicillium chrysogenum, as a novel lead for the control of c-Met-dependent breast cancer proliferation, migration and invasion.
Mady MS; Mohyeldin MM; Ebrahim HY; Elsayed HE; Houssen WE; Haggag EG; Soliman RF; El Sayed KA
Bioorg Med Chem; 2016 Jan; 24(2):113-22. PubMed ID: 26692349
[TBL] [Abstract][Full Text] [Related]
5. (-)-Oleocanthal as a c-Met inhibitor for the control of metastatic breast and prostate cancers.
Elnagar AY; Sylvester PW; El Sayed KA
Planta Med; 2011 Jul; 77(10):1013-9. PubMed ID: 21328179
[TBL] [Abstract][Full Text] [Related]
6. ψ-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling.
Ding J; Wen W; Xiang D; Yin P; Liu Y; Liu C; He G; Cheng Z; Yin J; Sheng C; Zhang W; Nan F; Ye W; Zhang X; Wang H
Oncotarget; 2015 May; 6(13):11627-39. PubMed ID: 25890498
[TBL] [Abstract][Full Text] [Related]
7. Rutin as A Novel c-Met Inhibitory Lead for The Control of Triple Negative Breast Malignancies.
Elsayed HE; Ebrahim HY; Mohyeldin MM; Siddique AB; Kamal AM; Haggag EG; El Sayed KA
Nutr Cancer; 2017; 69(8):1256-1271. PubMed ID: 29083228
[TBL] [Abstract][Full Text] [Related]
8. The HGF inhibitory peptide HGP-1 displays promising in vitro and in vivo efficacy for targeted cancer therapy.
Chen L; Li C; Zhu Y
Oncotarget; 2015 Oct; 6(30):30088-101. PubMed ID: 26254225
[TBL] [Abstract][Full Text] [Related]
9. Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.
Zhao Y; Zhang J; Tian Y; Xue C; Hu Z; Zhang L
Drug Des Devel Ther; 2015; 9():4897-907. PubMed ID: 26345996
[TBL] [Abstract][Full Text] [Related]
10. (1S,2E,4S,7E,11E)-2,7,11-Cembratriene-4,6-diol semisynthetic analogs as novel c-Met inhibitors for the control of c-Met-dependent breast malignancies.
Ebrahim HY; Mohyeldin MM; Hailat MM; El Sayed KA
Bioorg Med Chem; 2016 Nov; 24(22):5748-5761. PubMed ID: 27681240
[TBL] [Abstract][Full Text] [Related]
11. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
[TBL] [Abstract][Full Text] [Related]
12. 13
Souid S; Elsayed HE; Ebrahim HY; Mohyeldin MM; Siddique AB; Karoui H; El Sayed KA; Essafi-Benkhadir K
Mol Carcinog; 2018 Nov; 57(11):1507-1524. PubMed ID: 29978911
[TBL] [Abstract][Full Text] [Related]
13. Olive secoiridoids and semisynthetic bioisostere analogues for the control of metastatic breast cancer.
Busnena BA; Foudah AI; Melancon T; El Sayed KA
Bioorg Med Chem; 2013 Apr; 21(7):2117-27. PubMed ID: 23403296
[TBL] [Abstract][Full Text] [Related]
14. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
[TBL] [Abstract][Full Text] [Related]
15. Norstictic Acid Inhibits Breast Cancer Cell Proliferation, Migration, Invasion, and In Vivo Invasive Growth Through Targeting C-Met.
Ebrahim HY; Elsayed HE; Mohyeldin MM; Akl MR; Bhattacharjee J; Egbert S; El Sayed KA
Phytother Res; 2016 Apr; 30(4):557-66. PubMed ID: 26744260
[TBL] [Abstract][Full Text] [Related]
16. BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro.
Dai Y; Siemann DW
Mol Cancer Ther; 2010 Jun; 9(6):1554-61. PubMed ID: 20515943
[TBL] [Abstract][Full Text] [Related]
17. Potential Antitumor Activity of SIM-89 in Non-Small Cell Lung Cancer Cells.
Pei J; Chu T; Shao M; Teng J; Sha H; Gu A; Li R; Qian J; Mao W; Li Y; Han B
Yonsei Med J; 2017 May; 58(3):581-591. PubMed ID: 28332364
[TBL] [Abstract][Full Text] [Related]
18. Boswellia frereana suppresses HGF-mediated breast cancer cell invasion and migration through inhibition of c-Met signalling.
Parr C; Ali AY
J Transl Med; 2018 Oct; 16(1):281. PubMed ID: 30314527
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
[TBL] [Abstract][Full Text] [Related]
20. EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors.
Bladt F; Faden B; Friese-Hamim M; Knuehl C; Wilm C; Fittschen C; Grädler U; Meyring M; Dorsch D; Jaehrling F; Pehl U; Stieber F; Schadt O; Blaukat A
Clin Cancer Res; 2013 Jun; 19(11):2941-51. PubMed ID: 23553846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
